EP1567506A4 - Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors - Google Patents
Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitorsInfo
- Publication number
- EP1567506A4 EP1567506A4 EP03768789A EP03768789A EP1567506A4 EP 1567506 A4 EP1567506 A4 EP 1567506A4 EP 03768789 A EP03768789 A EP 03768789A EP 03768789 A EP03768789 A EP 03768789A EP 1567506 A4 EP1567506 A4 EP 1567506A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cyanoamidines
- cyanoguanidines
- erbb2
- egfr inhibitors
- egfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42754402P | 2002-11-20 | 2002-11-20 | |
US427544P | 2002-11-20 | ||
PCT/US2003/035670 WO2004046101A2 (en) | 2002-11-20 | 2003-11-10 | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1567506A2 EP1567506A2 (en) | 2005-08-31 |
EP1567506A4 true EP1567506A4 (en) | 2007-06-20 |
Family
ID=32326558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03768789A Withdrawn EP1567506A4 (en) | 2002-11-20 | 2003-11-10 | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1567506A4 (en) |
JP (1) | JP4611745B2 (en) |
AU (1) | AU2003291394B2 (en) |
CA (1) | CA2506503A1 (en) |
NZ (1) | NZ540092A (en) |
WO (1) | WO2004046101A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
CN108285421A (en) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | A kind of method of micro passage reaction synthesis lapatinib intermediate |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6562319B2 (en) | 2001-03-12 | 2003-05-13 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy |
MXPA06001989A (en) * | 2003-08-18 | 2006-05-17 | Pfizer Prod Inc | Dosing schedule for erbb2 anticancer agents. |
EP1673110A2 (en) * | 2003-09-11 | 2006-06-28 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy |
WO2006031929A2 (en) | 2004-09-15 | 2006-03-23 | Janssen Pharmaceutica, N.V. | Thiazolopyridine kinase inhibitors |
US7579356B2 (en) | 2005-05-04 | 2009-08-25 | Janssen Pharmaceutica Nv | Thia-tetraazaacenaphthylene kinase inhibitors |
DE102006012251A1 (en) * | 2006-03-15 | 2007-11-08 | Grünenthal GmbH | Substituted 4-aminoquinazoline derivatives and their use for the preparation of medicaments |
CL2007003158A1 (en) | 2006-11-02 | 2008-05-16 | Astrazeneca Ab | PROCEDURE FOR PREPARATION OF COMPOUNDS DERIVED FROM QUINAZOLINA OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS; INTERMEDIARY COMPOUNDS; PREPARATION PROCEDURE |
JP2011502141A (en) | 2007-10-29 | 2011-01-20 | ナトコ ファーマ リミテッド | 4- (Tetrazol-5-yl) -quinazoline derivatives as anticancer agents |
WO2011002523A1 (en) | 2009-07-02 | 2011-01-06 | Kanionusa Inc. | Phosphorus containing quinazoline compounds and methods of use |
JP2016510000A (en) | 2013-02-20 | 2016-04-04 | カラ ファーマシューティカルズ インコーポレイテッド | Therapeutic compounds and uses thereof |
US9688688B2 (en) | 2013-02-20 | 2017-06-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof |
US9890173B2 (en) | 2013-11-01 | 2018-02-13 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
CA2928658A1 (en) | 2013-11-01 | 2015-05-07 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10710968B2 (en) | 2016-01-13 | 2020-07-14 | Hadasit Medical Research Services And Development Ltd. | Radiolabeled erlotinib analogs and uses thereof |
US10253036B2 (en) | 2016-09-08 | 2019-04-09 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
US10392399B2 (en) | 2016-09-08 | 2019-08-27 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
AU2017324251A1 (en) | 2016-09-08 | 2019-03-21 | Kala Pharmaceuticals, Inc. | Crystalline forms of therapeutic compounds and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1067123A1 (en) * | 1998-03-31 | 2001-01-10 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogenous heterocyclic compounds |
EP1110953A1 (en) * | 1995-03-30 | 2001-06-27 | Pfizer Inc. | Quinazoline derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
PL194689B1 (en) * | 1996-02-13 | 2007-06-29 | Astrazeneca Uk Ltd | Derivatives of quinazoline |
HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
GB2345486A (en) | 1999-01-11 | 2000-07-12 | Glaxo Group Ltd | Heteroaromatic protein tyrosine kinase inhibitors |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
MXPA02012870A (en) | 2000-06-22 | 2003-05-14 | Pfizer Prod Inc | Substituted bicyclic derivatives for the treatment of abnormal cell growth. |
-
2003
- 2003-11-10 EP EP03768789A patent/EP1567506A4/en not_active Withdrawn
- 2003-11-10 NZ NZ540092A patent/NZ540092A/en not_active IP Right Cessation
- 2003-11-10 WO PCT/US2003/035670 patent/WO2004046101A2/en active Application Filing
- 2003-11-10 JP JP2004553551A patent/JP4611745B2/en not_active Expired - Fee Related
- 2003-11-10 CA CA002506503A patent/CA2506503A1/en not_active Abandoned
- 2003-11-10 AU AU2003291394A patent/AU2003291394B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1110953A1 (en) * | 1995-03-30 | 2001-06-27 | Pfizer Inc. | Quinazoline derivatives |
EP1067123A1 (en) * | 1998-03-31 | 2001-01-10 | Kyowa Hakko Kogyo Co., Ltd. | Nitrogenous heterocyclic compounds |
Non-Patent Citations (2)
Title |
---|
No further relevant documents disclosed * |
See also references of WO2004046101A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9353122B2 (en) | 2013-02-15 | 2016-05-31 | Kala Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
CN108285421A (en) * | 2018-01-26 | 2018-07-17 | 黑龙江鑫创生物科技开发有限公司 | A kind of method of micro passage reaction synthesis lapatinib intermediate |
Also Published As
Publication number | Publication date |
---|---|
WO2004046101A3 (en) | 2004-09-16 |
JP2006508979A (en) | 2006-03-16 |
CA2506503A1 (en) | 2004-06-03 |
AU2003291394B2 (en) | 2009-06-25 |
NZ540092A (en) | 2007-06-29 |
AU2003291394A1 (en) | 2004-06-15 |
EP1567506A2 (en) | 2005-08-31 |
WO2004046101A2 (en) | 2004-06-03 |
JP4611745B2 (en) | 2011-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1567506A4 (en) | Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors | |
IL165046A0 (en) | Pyrimidinone compounds, compositions and methods | |
EG25482A (en) | Inhibitors | |
IL169112A0 (en) | Phosphonooxy quinazoline derivatives and their pharmaceuitical use | |
HK1089277A1 (en) | Scheme for spreading and facilitating remote e-services | |
AU2003259749A1 (en) | 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors | |
ZA200500680B (en) | Quinoline derivatives and their use as mycrobacterial inhibitors | |
AU2003262747A8 (en) | Compounds, compositions, and methods | |
AU2003236527A8 (en) | Compounds, compositions, and methods | |
AU2003265242A8 (en) | Compounds, compositions, and methods | |
HK1070656A1 (en) | Compounds, compositions, and methods | |
EP1553931A4 (en) | Compounds, compositions, and methods | |
EP1575495A4 (en) | Compounds and methods | |
EP1581520A4 (en) | Compounds, compositions and methods | |
IL167936A0 (en) | Compounds, compositions,and methods | |
AU2003256805A8 (en) | Compounds compositions and methods | |
AU2003232848A8 (en) | Phenylaminopyrimidines and their use as rho-kinase inhibitors | |
AU2003277079A8 (en) | Compounds, compositions, and methods | |
GB0220385D0 (en) | Compound and process | |
ZA200409691B (en) | Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors | |
AU2003267169A8 (en) | Compounds, compositions and methods | |
AU2003300031A8 (en) | Compounds, compositions, and methods | |
GB2389644B (en) | Mouse | |
GB0215867D0 (en) | Novel method and compounds | |
GB0211751D0 (en) | Compound and process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050614 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1080861 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070521 |
|
17Q | First examination report despatched |
Effective date: 20081119 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110218 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1080861 Country of ref document: HK |